Anti-TNF agents used in patients who did not develop TB were adalimumab, infliximab (IFX), etanercept (ETN) and certolizumab pegol in 29 (47.5%), 21 (34.4%), 8 (13.1%) and 3 (4.9%) cases, respectively, with no statistical significance. Here, TNF is linked to tuberculosis.